HUP0401461A2 - 1-Fenilszulfonil-1,3-dihidro-2H-indol-2-on-származékok, a vegyületek előállítása és terápiás alkalmazása - Google Patents
1-Fenilszulfonil-1,3-dihidro-2H-indol-2-on-származékok, a vegyületek előállítása és terápiás alkalmazásaInfo
- Publication number
- HUP0401461A2 HUP0401461A2 HU0401461A HUP0401461A HUP0401461A2 HU P0401461 A2 HUP0401461 A2 HU P0401461A2 HU 0401461 A HU0401461 A HU 0401461A HU P0401461 A HUP0401461 A HU P0401461A HU P0401461 A2 HUP0401461 A2 HU P0401461A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- compounds
- halogen atom
- receptors
- alkoxy group
- Prior art date
Links
- HBORMJBGPGQHSF-UHFFFAOYSA-N 1-(benzenesulfonyl)-3h-indol-2-one Chemical class O=C1CC2=CC=CC=C2N1S(=O)(=O)C1=CC=CC=C1 HBORMJBGPGQHSF-UHFFFAOYSA-N 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 229940127557 pharmaceutical product Drugs 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 102000004136 Vasopressin Receptors Human genes 0.000 abstract 1
- 108090000643 Vasopressin Receptors Proteins 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
- 239000013067 intermediate product Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000011707 mineral Substances 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 235000005985 organic acids Nutrition 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
Abstract
A találmány tárgya (I) általános képletű vegyületek, a képletben - nértéke 1 vagy 2; - X jelentése -CH2-; -O-; -NH-; -O-CH2-; -NH-CH2-; -NH-CH2-CH2- csoport; - R, jelentése halogénatom; 1-4 szénatomosalkilcsoport; 1-4 szénatomos alkoxicsoport; - R2 jelentésehidrogénatom; halogénatom; alkilcsoport; alkoxicsoport;trifluormetilcsoport; - R3 jelentése halogénatom; alkilcsoport;alkoxicsoport; trifluormetilcsoport; trifluormetoxicsoport; - R4jelentése hidrogénatom; halogénatom; alkilcsoport; alkoxicsoport; - R5jelentése egy 5- vagy 6-tagú heteroaromás csoport; - R6 és R7jelentése alkoxicsoport; és a vegyületek ásványi vagy szerves savakkalalkotott sóira, szolvátjaira és/vagy hidrátjaira vonatkozik, amelyek aV1b arginin-vazopresszin receptorok és/vagy azoxitocin receptorok,ezen túlmenően bizonyos vegyületek a V1a receptorok iránt mutatnakaffinitást. A találmány tárgyát képezi a vegyületek előállításáraalkalmas eljárás, valamint az előállítási eljárás közbenső termékei, avegyületeket tartalmazó gyógyszertermékek és a vegyületekgyógyszertermékek előállítására való alkalmazása. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0110359A FR2827604B1 (fr) | 2001-07-17 | 2001-07-17 | Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
PCT/FR2002/002500 WO2003008407A2 (fr) | 2001-07-17 | 2002-07-15 | Derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0401461A2 true HUP0401461A2 (hu) | 2004-12-28 |
HUP0401461A3 HUP0401461A3 (en) | 2009-06-29 |
Family
ID=8866211
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0401461A HUP0401461A3 (en) | 2001-07-17 | 2002-07-15 | Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use |
Country Status (32)
Country | Link |
---|---|
US (1) | US7119086B2 (hu) |
EP (1) | EP1419150B1 (hu) |
JP (1) | JP4262088B2 (hu) |
KR (1) | KR20040017325A (hu) |
CN (1) | CN1224623C (hu) |
AR (1) | AR034792A1 (hu) |
AT (1) | ATE294171T1 (hu) |
AU (1) | AU2002340999B2 (hu) |
BR (1) | BR0211284A (hu) |
CA (1) | CA2450437A1 (hu) |
CO (1) | CO5550440A2 (hu) |
DE (1) | DE60203917T2 (hu) |
DK (1) | DK1419150T3 (hu) |
EA (1) | EA006019B1 (hu) |
ES (1) | ES2240814T3 (hu) |
FR (1) | FR2827604B1 (hu) |
HK (1) | HK1061679A1 (hu) |
HR (1) | HRP20040027A2 (hu) |
HU (1) | HUP0401461A3 (hu) |
IL (1) | IL159275A0 (hu) |
IS (1) | IS2485B (hu) |
MA (1) | MA27049A1 (hu) |
ME (1) | MEP24508A (hu) |
MX (1) | MXPA04000507A (hu) |
NO (1) | NO20040219L (hu) |
NZ (1) | NZ530144A (hu) |
PL (1) | PL366829A1 (hu) |
PT (1) | PT1419150E (hu) |
RS (1) | RS204A (hu) |
UA (1) | UA77181C2 (hu) |
WO (1) | WO2003008407A2 (hu) |
ZA (1) | ZA200309717B (hu) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7754711B2 (en) * | 2003-07-30 | 2010-07-13 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
WO2005018531A2 (fr) * | 2003-08-26 | 2005-03-03 | 'chemical Diversity Research Institute', Ltd. | Compositions pharmaceutiques, composes azo-heterocycliques et procedes de fabrication et d'utilisation correspondants |
US7528124B2 (en) | 2003-08-28 | 2009-05-05 | Taisho Pharmaceutical Co., Ltd. | 1,3-dihydro-2H-indol-2-one derivative |
US20050070718A1 (en) * | 2003-09-30 | 2005-03-31 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
US8580842B2 (en) * | 2003-09-30 | 2013-11-12 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
AU2005237520B2 (en) | 2004-04-27 | 2012-01-19 | Wyeth | Purification of progesterone receptor modulators |
DE102004033834A1 (de) | 2004-07-13 | 2006-02-02 | Abbott Gmbh & Co. Kg | Substituierte Oxindol-Derivate und diese enthaltende Arzneimittel |
WO2006070742A1 (ja) * | 2004-12-27 | 2006-07-06 | Kyoto University | 麻薬性鎮痛剤の耐性形成抑制剤 |
JP5125501B2 (ja) * | 2005-01-28 | 2013-01-23 | 大正製薬株式会社 | 1,3−ジヒドロ−2h−インドール−2−オン化合物、及び芳香族複素環が縮合したピロリジン−2−オン化合物 |
CA2602194A1 (en) | 2005-03-24 | 2006-09-28 | Abbott Gmbh & Co. Kg | Substituted oxindol derivatives, drugs containing said derivatives and the use thereof |
DE102005014936A1 (de) * | 2005-03-24 | 2006-12-14 | Abbott Gmbh & Co. Kg | Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung |
DE102005014904A1 (de) * | 2005-03-26 | 2007-02-01 | Abbott Gmbh & Co. Kg | Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung |
US7576082B2 (en) | 2005-06-24 | 2009-08-18 | Hoffman-La Roche Inc. | Oxindole derivatives |
SG132540A1 (en) | 2005-11-25 | 2007-06-28 | Matsushita Electric Ind Co Ltd | Magnetic trap for ferrous contaminants in lubricant |
JP2009517444A (ja) | 2005-12-02 | 2009-04-30 | アボット ゲーエムベーハー ウント カンパニー カーゲー | 置換オキシインドール誘導体、それを含む医薬およびそれの使用 |
DE102006040915A1 (de) * | 2006-08-26 | 2008-03-20 | Abbott Gmbh & Co. Kg | Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung |
CN101528712B (zh) * | 2006-08-26 | 2013-10-30 | Abbvie德国有限责任两合公司 | 取代的苯并咪唑酮衍生物、包含它们的药物以及其用途 |
US20080167286A1 (en) * | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
US8486979B2 (en) | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
CN101611028B (zh) * | 2006-12-30 | 2013-09-11 | 艾博特股份有限两合公司 | 取代的羟吲哚衍生物、以及它们用作加压素受体配体的用途 |
UY30846A1 (es) | 2006-12-30 | 2008-07-31 | Abbott Gmbh & Amp | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos |
RU2461556C2 (ru) * | 2006-12-30 | 2012-09-20 | Эбботт Гмбх Унд Ко. Кг | Замещенные производные оксидола и их применение в качестве лигандов рецептора вазопрессина |
US8486931B2 (en) * | 2007-03-02 | 2013-07-16 | Abbott Gmbh & Co. Kg | Substituted oxindole compounds |
FR2920023B1 (fr) * | 2007-08-16 | 2013-02-08 | Sanofi Aventis | Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique |
US8546401B2 (en) | 2007-12-07 | 2013-10-01 | AbbVie Deutschland GmbH & Co. KG | 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressin-dependent diseases |
RU2484090C2 (ru) * | 2007-12-07 | 2013-06-10 | Эбботт Гмбх Унд Ко.Кг | 5-галогензамещенные производные оксиндола и их применение для лечения вазопрессинзависимых заболеваний |
WO2009071691A2 (de) * | 2007-12-07 | 2009-06-11 | Abbott Gmbh & Co. Kg | Oxindol-derivate und ihre verwendung als medikament |
WO2010009775A1 (de) * | 2007-12-07 | 2010-01-28 | Abbott Gmbh & Co. Kg | Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen |
JP5701607B2 (ja) | 2007-12-07 | 2015-04-15 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | アミドメチル置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用 |
CA2710946C (en) * | 2007-12-27 | 2016-05-31 | Abbott Gmbh & Co. Kg | Substituted oxindole-derivatives and the use thereof for the treatment of vasopressin-dependent illnesses |
FR2927625B1 (fr) * | 2008-02-19 | 2010-03-12 | Sanofi Aventis | Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique |
FR2930249B1 (fr) * | 2008-04-21 | 2010-05-14 | Sanofi Aventis | Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique. |
WO2010017827A1 (en) * | 2008-08-14 | 2010-02-18 | European Molecular Biology Laboratory | 6-substituted 1-sulfonyl-2, 3-dihydro-indole derivatives for the treatment of proliferative diseases |
RS59913B1 (sr) | 2008-10-17 | 2020-03-31 | Sanofi Aventis Deutschland | Kombinacija insulina i glp-1-agonista |
FR2941946B1 (fr) | 2009-02-12 | 2011-03-25 | Sanofi Aventis | Derives de 3-benzofuranyl-indol-2-one-3-acetamidopiperazines substitues, leur preparation et leur application en therapeutique |
FR2941947B1 (fr) | 2009-02-12 | 2011-03-25 | Sanofi Aventis | Derives de 3-benzofuranyl-indol-2-one subtitues en 3, leur preparation et leur application en therapeutique |
WO2010138600A2 (en) | 2009-05-29 | 2010-12-02 | Abbott Laboratories | Pharmaceutical compositions for the treatment of pain |
WO2010142739A1 (en) * | 2009-06-10 | 2010-12-16 | Abbott Gmbh & Co. Kg | Use of substituted oxindole derivatives for the treatment and prophylaxis of pain |
KR101972301B1 (ko) | 2009-11-13 | 2019-04-25 | 사노피-아벤티스 도이칠란트 게엠베하 | Glp-1 작용제, 인슐린 및 메티오닌을 포함하는 약제학적 조성물 |
BR112012011403B8 (pt) | 2009-11-13 | 2021-05-25 | Sanofi Aventis Deutschland | composição farmacêutica líquida compreendendo um agonista glp-1 e metionina e uso da mesma |
US8088815B2 (en) | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
US8288431B2 (en) | 2010-02-17 | 2012-10-16 | Hoffmann-La Roche Inc. | Substituted spiroindolinones |
US8217044B2 (en) | 2010-04-28 | 2012-07-10 | Hoffmann-La Roche Inc. | Spiroindolinone pyrrolidines |
AU2011202239C1 (en) * | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
CA2809321C (en) | 2010-08-30 | 2018-08-14 | Sanofi-Aventis Deutschland Gmbh | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 |
US9096551B2 (en) | 2010-12-21 | 2015-08-04 | Bayer Intellectual Property Gmbh | Method for producing 2-(triazinylcarbonyl) sulfonanilides |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
HUE027989T2 (hu) | 2011-08-29 | 2016-11-28 | Sanofi Aventis Deutschland | Gyógyászati készítmény 2-es típusú cukorbetegségben szenvedõ betegek glikémiás kontrolljában történõ alkalmazásra |
AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
WO2014161837A1 (en) | 2013-04-03 | 2014-10-09 | Sanofi | Treatment of diabetes mellitus by long–acting formulations of insulins |
SI3229828T1 (sl) | 2014-12-12 | 2023-06-30 | Sanofi-Aventis Deutschland Gmbh | Formulacija s fiksnim razmerjem inzulin glargin/liksisenatid |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
EP3912625A1 (en) * | 2020-05-20 | 2021-11-24 | Kaerus Bioscience Limited | Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders |
KR20230090589A (ko) * | 2021-12-15 | 2023-06-22 | 국립해양생물자원관 | 성게 유래 펩타이드 및 이의 용도 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2714378B1 (fr) | 1993-12-24 | 1996-03-15 | Sanofi Sa | Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant. |
GB2326639A (en) * | 1997-06-18 | 1998-12-30 | Merck & Co Inc | Piperazine Oxytocin Receptor Antagonists |
US20050070718A1 (en) * | 2003-09-30 | 2005-03-31 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
-
2001
- 2001-07-17 FR FR0110359A patent/FR2827604B1/fr not_active Expired - Fee Related
-
2002
- 2002-07-15 KR KR10-2004-7000787A patent/KR20040017325A/ko active IP Right Grant
- 2002-07-15 DK DK02774822T patent/DK1419150T3/da active
- 2002-07-15 ME MEP-245/08A patent/MEP24508A/xx unknown
- 2002-07-15 BR BR0211284-1A patent/BR0211284A/pt not_active IP Right Cessation
- 2002-07-15 PL PL02366829A patent/PL366829A1/xx not_active Application Discontinuation
- 2002-07-15 AT AT02774822T patent/ATE294171T1/de active
- 2002-07-15 IL IL15927502A patent/IL159275A0/xx unknown
- 2002-07-15 CA CA002450437A patent/CA2450437A1/en not_active Abandoned
- 2002-07-15 ES ES02774822T patent/ES2240814T3/es not_active Expired - Lifetime
- 2002-07-15 RS YU204A patent/RS204A/sr unknown
- 2002-07-15 DE DE60203917T patent/DE60203917T2/de not_active Expired - Lifetime
- 2002-07-15 NZ NZ530144A patent/NZ530144A/en not_active IP Right Cessation
- 2002-07-15 UA UA20031212069A patent/UA77181C2/uk unknown
- 2002-07-15 PT PT02774822T patent/PT1419150E/pt unknown
- 2002-07-15 US US10/484,370 patent/US7119086B2/en not_active Expired - Fee Related
- 2002-07-15 AU AU2002340999A patent/AU2002340999B2/en not_active Ceased
- 2002-07-15 HU HU0401461A patent/HUP0401461A3/hu unknown
- 2002-07-15 CN CNB028142624A patent/CN1224623C/zh not_active Expired - Fee Related
- 2002-07-15 WO PCT/FR2002/002500 patent/WO2003008407A2/fr active IP Right Grant
- 2002-07-15 EA EA200301306A patent/EA006019B1/ru not_active IP Right Cessation
- 2002-07-15 MX MXPA04000507A patent/MXPA04000507A/es active IP Right Grant
- 2002-07-15 JP JP2003513966A patent/JP4262088B2/ja not_active Expired - Fee Related
- 2002-07-15 EP EP02774822A patent/EP1419150B1/fr not_active Expired - Lifetime
- 2002-07-16 AR ARP020102655A patent/AR034792A1/es unknown
-
2003
- 2003-12-15 ZA ZA200309717A patent/ZA200309717B/en unknown
- 2003-12-15 IS IS7079A patent/IS2485B/is unknown
-
2004
- 2004-01-09 MA MA27476A patent/MA27049A1/fr unknown
- 2004-01-12 HR HR20040027A patent/HRP20040027A2/xx not_active Application Discontinuation
- 2004-01-14 CO CO04002002A patent/CO5550440A2/es not_active Application Discontinuation
- 2004-01-16 NO NO20040219A patent/NO20040219L/no not_active Application Discontinuation
- 2004-06-25 HK HK04104546A patent/HK1061679A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0401461A2 (hu) | 1-Fenilszulfonil-1,3-dihidro-2H-indol-2-on-származékok, a vegyületek előállítása és terápiás alkalmazása | |
HUP0204242A2 (en) | Novel 1,3-dihydro-2h-indol-2-one derivatives, their preparation and pharmaceutical compositions compositions containing them | |
ATE233256T1 (de) | 2-pyrimidinamin derivaten und verfahrens zu deren herstellung | |
HUP0004082A2 (hu) | Adenozinszármazékok, eljárás előállításukra azokat hatóanyagként tartalmazó gyógyszerkészítmények, valamint ilyen hatóanyagok alkalmazása gyógyszerkészítmények előállítására | |
HRP20050213A2 (en) | 2,4-substituted indoles and their use as 5-ht6 modulators | |
HUP0105414A2 (hu) | Pirrolo-izokinolin-, azepino- és diazepino-indol-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
HUP0400527A2 (hu) | Benzoil-piridin-származékok vagy sóik, ezeket aktív alkotórészként tartalmazó fungicidek, eljárás ezek előállítására, és köztes termékek ezek előállításához | |
CY1109227T1 (el) | Παραγωγα της 5-φαινυλο-4-μεθυλο-θειαζολ-2-υλ-αμινης ως αναστολεις των ενζυμων κινασης της φωσφατιδυλινοσιτολης 3 (p13) για την θεραπεια των φλεγμονωδων ασθενειων των αεραγωγων | |
HUP0103460A2 (hu) | Vírusellenes hatású indolszármazékok és a vegyületeket tartalmazó gyógyszerkészítmények | |
HUP0402454A2 (hu) | Szubsztituált kinazolinszármazékok mint az aurora kinázok inhibitorai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
AU1760288A (en) | Pyrazolopyridine compound and processes for preparation thereof | |
NO308736B1 (no) | 1,2-difenylpyrrolderivater, farmasøytiske preparater inneholdende disse, og deres anvendelse | |
HUP9701265A2 (hu) | Imidazolinszármazékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítények | |
DE60139639D1 (de) | Substituierte thiazolderivate mit 3-pyridylgruppen, verfahren zu deren herstellung und deren verwendung | |
NZ233752A (en) | Substituted quinoline derivatives, preparation and pharmaceutical compositions thereof | |
HUP0100865A2 (hu) | Meta-azaciklusos csoporttal N-szubsztituált amino-benzoesav-vegyületek és származékaik mint integrin antagonista hatóanyagok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP9901452A2 (hu) | Biciklusos aromás vegyületek és ilyen vegyületeket tartalmazó gyógyszerkészítmények | |
HUP0401235A2 (hu) | 5-HT6 receptor affinitással rendelkező arilszulfonil-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények | |
MX9806171A (es) | Derivados 2,3-benzodiazepina y sus usos como inhibidores del receptor-ampa. | |
FR2665441B1 (fr) | Derives de la n-sulfonyl indoline, leur preparation, les compositions pharmaceutiques en contenant. | |
HUP0004142A2 (hu) | 5-HT1F agonista hatású karboxamidszármazékok és a vegyületeket tartalmazó gyógyászati készítmények | |
HUP0001165A2 (hu) | NK1 és NK2 antagonista hatású acil-amino-alkil-amid-származékok, a vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra | |
HUP9700708A2 (hu) | N-[(9-pirimido[1,2-a]indolil)-metil-fenil-acetil]-fenil-glicinol-származékok, az ezeket tartalmazó gyógyszerkészítmények, eljárás előállításukra és intermedierjeik | |
HUP9904218A2 (hu) | SPLA2 inhibitorokként alkalmazható fenil-glioxamidok | |
HUP0100785A2 (hu) | Indolszármazékok, eljárás előállításukra és ezeket a vegyületeket tartalmazó gyógyászati készítmények |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |